In this GEN webinar, Asimov’s co-founder and CEO Alec Nielsen, PhD, will show how Asimov combines bio-foundation models, AI agents, and synthetic biology to augment development workflows.
In this GEN webinar, Chris Nieder, an expert in viral vector programs, will examine how strategically designed preclinical manufacturing campaigns provide a practical foundation for GMP production.
In this GEN webinar, our expert speaker Josh Wheeler, MD, PhD, will discuss a biology-first, interpretable AI approach to understand patient tumor states and next-generation preclinical models that reproduce their biological complexity.
In this GEN webinar, Mirjana Efremova, PhD (Queen Mary University of London) will show how these technologies can be used to analyze primary and liver-metastatic CRC patient samples to reveal cancer cell states.
In this GEN webinar, our expert panelists will discuss some of the scientific and practical barriers that are facing brain organoid research and strategies for improving organoid-to-organoid and experiment-to-experiment consistency.
In this GEN webinar, our expert speaker Joshua Michael Hare, MD, will examine how therapeutically relevant research is helping shape the development of cell therapies for cardiovascular disease.
In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or complementary mechanisms.
In this GEN webinar, our expert speaker, Emily Gaither, will present a systematic path from high-throughput resin screening to the selection and sequencing of two polishing steps, using emicizumab, an asymmetric IgG4 bsAb as a case study.
In this GEN webinar, our expert speaker Angela M. Cacace, PhD, will discuss the increasing rationale for targeting key drivers of neurological disease with protein degraders and how this approach may enable deeper, more precise modulation of disease biology.
In this GEN webinar, our expert speaker, Sam Zhang, PhD, will discuss emerging trends and capacity needs across the global late-stage microbial pipeline and CDMO landscape.
In this GEN webinar, experts from Rose BioSolutions, a CDMO and Cell Solutions organization formed from Charles River Laboratories’ businesses, will discuss how integrating regulatory strategy at the earliest stages of development can reduce overall risk and improve program outcomes.
In this GEN webinar, speakers from Flock Bio and Ribbon Bio will explore how bench-based, cell-free DNA production can complement expertise in custom DNA design and manufacturing.
